RBM10 and cancer: Interestingly, the cancer-derived RBM10-I316F mutant fails to reduce the protein level and activity of c-Myc (Figs. 5 and 7 G–K, ); instead, this RBM10 mutant appeared to augment the c-Myc level and activity (Figs. 5 and 7 G–K, ).